Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Kai-Hsin Liao"'
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 916-922 (2020)
Drug lag—delayed approval or reimbursement—is a major barrier to accessing cutting‐edge drugs. Unlike approval lag, reimbursement lag is under‐researched. We investigated the key determinants of reimbursement lag under Taiwan National Health
Externí odkaz:
https://doaj.org/article/e1ddebf6d9ee4a57aee0b003ea8b4737
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
Objective Cancers result in significant economic burdens on patients, health sectors and society. Reliable burden estimates will help guide resource allocation. This study aimed to perform a nationwide cost analysis of the direct and indirect costs o
Externí odkaz:
https://doaj.org/article/dba43b730c1f4b7598c2811f13c7b465
Publikováno v:
Clinical and Translational Science
Healthcare expenditure on pharmaceuticals, especially innovative oncology drugs, is escalating. Current knowledge on this topic is largely limited to studies conducted upon reimbursement of new drugs. We investigated how endogenous factors (e.g., cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a0cd05bd6dcb86f64a8828c9d98084f
https://doi.org/10.1111/cts.12829
https://doi.org/10.1111/cts.12829
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 13, Iss 5, Pp 916-922 (2020)
Clinical and Translational Science, Vol 13, Iss 5, Pp 916-922 (2020)
Drug lag—delayed approval or reimbursement—is a major barrier to accessing cutting‐edge drugs. Unlike approval lag, reimbursement lag is under‐researched. We investigated the key determinants of reimbursement lag under Taiwan National Health
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71496893d72d7f8cf56f4caaf3df989d
http://europepmc.org/articles/PMC7485943
http://europepmc.org/articles/PMC7485943
Autor:
Anthony W. Tolcher, Steven Pirie-Shepherd, Robert Wesolowski, Brenda Gibson, Lee S. Rosen, Steven Y. Hua, Kai-Hsin Liao, Raffaele Baffa
Publikováno v:
Investigational New Drugs. 38:120-130
Background PF-06650808 is a novel anti-Notch3 antibody–drug conjugate (ADC) able to deliver an auristatin-based cytotoxic payload to target cells. In this first-in-human, dose-finding, phase I study (NCT02129205), we investigated safety, pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a683116c97ca88234178e12efdc152ad
https://doi.org/10.1007/s10637-019-00754-y
https://doi.org/10.1007/s10637-019-00754-y
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
BMJ Open
BMJ Open
ObjectivesThe UK government is proposing to cease cutting the local authority public health grant by reallocating part of the treatment budget to preventative activity. This study examines whether this proposal is evidenced based and, in particular,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbfa4f73751aff5149625a9ea419e40d
https://eprints.whiterose.ac.uk/167548/1/e036411.full.pdf
https://eprints.whiterose.ac.uk/167548/1/e036411.full.pdf
Publikováno v:
BMJ Open, Vol 10, Iss 10 (2020)
BMJ Open
BMJ Open
ObjectiveCancers result in significant economic burdens on patients, health sectors and society. Reliable burden estimates will help guide resource allocation. This study aimed to perform a nationwide cost analysis of the direct and indirect costs of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecbed87679ea4e423c118d8561b69c8
https://bmjopen.bmj.com/content/10/10/e036341.full
https://bmjopen.bmj.com/content/10/10/e036341.full
Autor:
Hong Liang, Pamela D. Garzone, Kai-Hsin Liao, Xu Meng, Chandrasekhar Udata, Barry Gumbiner, Jason H. Williams, Tenshang Joh
Publikováno v:
The Journal of Clinical Pharmacology. 57:855-864
Bococizumab (RN316/PF-04950615), a humanized monoclonal antibody, binds to secreted proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevents its downregulation of low-density lipoprotein receptor, leading to improved clearance and reduction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a45cd39dea36f550d918e6b8c1719e73
https://doi.org/10.1002/jcph.867
https://doi.org/10.1002/jcph.867
Publikováno v:
Journal of Clinical Oncology. 39:3093-3093
3093 Background: In oncology, the recommended phase 2 dose (RP2D) is typically selected from the first-in-patient (FIP) dose escalation and then carried forward to late stage trials. The RP2D is often informed by limited data from a relatively small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73dbf4a84b03faae2a613992c051a95c
https://doi.org/10.1200/jco.2021.39.15_suppl.3093
https://doi.org/10.1200/jco.2021.39.15_suppl.3093
Autor:
Meng Li, I-Ming Wang, Michael L. Maitland, Cesar A. Perez, Ira Jacobs, Frank Tsai, Jordi Rodon Ahnert, Lada Markovtsova, Kit Man Wong, Jordan Berlin, Nora Cavazos, Anthony W. Tolcher, Kai Hsin Liao
Publikováno v:
Journal of Clinical Oncology. 39:3019-3019
3019 Background: Protein arginine methyltransferase 5 (PRMT5) methylates multiple substrates known to be dysregulated in cancer, including components of the spliceosome machinery. PF-06939999 is a selective small-molecule inhibitor of PRMT5. Here we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02e4be768e20ad2b328aaebe5c3f73ab
https://doi.org/10.1200/jco.2021.39.15_suppl.3019
https://doi.org/10.1200/jco.2021.39.15_suppl.3019